4D Molecular Therapeutics (FDMT) Fundamentals 2026 — Revenue Analysis | SniperIQ

1.13 on the NASDAQ. This SniperIQ fundamentals page covers 4D Molecular Therapeutics's valuation, profitability (net margin -182.3%), revenue ($85M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is 4D Molecular Therapeutics's market cap?

4D Molecular Therapeutics (FDMT) has a market capitalization of approximately $582M, trading at

1.13 on the NASDAQ. Market cap moves with the live share price.

What is 4D Molecular Therapeutics's P/E ratio?

4D Molecular Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is 4D Molecular Therapeutics?

4D Molecular Therapeutics runs a net profit margin of -182.3%, a gross margin of -12.4%, and an operating margin of -203.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does 4D Molecular Therapeutics generate?

4D Molecular Therapeutics reported revenue of $85M for fiscal year 2025, with net income of -

40M and earnings per share (EPS) of -2.42. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does 4D Molecular Therapeutics pay a dividend?

4D Molecular Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is 4D Molecular Therapeutics financially healthy?

4D Molecular Therapeutics carries a debt-to-equity ratio of 0.05x and a current ratio of 9.34x, with a market beta of 2.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is 4D Molecular Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For 4D Molecular Therapeutics (FDMT) the key facts are: market cap $582M, revenue $85M, 52-week range 4.274-14. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.